{"schema_version":"secwatch.filing_event.v1","accession":"0000886744-25-000007","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.624811+00:00","generated_at":"2026-05-22T10:14:39.663736+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Geron Q1: RYTELO revenue $39.4M; demand flat; EU approval granted for LR-MDS","bullets":["RYTELO net product revenue $39.4M in Q1 2025; demand up only 1% vs prior 13 weeks due to inventory drawdown.","European Commission granted marketing authorization for RYTELO; launch in select EU countries planned for 2026.","Phase 3 IMpactMF trial for R/R myelofibrosis ~85% enrolled; interim OS analysis expected 2H 2026.","Net loss improved to $19.8M ($0.03/share) vs $55.4M ($0.09/share) in Q1 2024 on first product revenue.","FY2025 total operating expense guidance maintained at $270M-$285M; cash $457.5M as of March 31."],"urls":{"canonical":"https://secwatch.observer/filing/0000886744-25-000007","json":"https://secwatch.observer/filing/0000886744-25-000007.json","markdown":"https://secwatch.observer/filing/0000886744-25-000007.md","text":"https://secwatch.observer/filing/0000886744-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/0000886744-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/gern-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T10:14:39.663736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}